Distinguishing benign renal masses from malignant renal tumours, and further differentiating indolent from aggressive renal cancers, on computed tomography (CT) scans remains challenging.
A 66-year-old New Hampshire man received the kidney as part of a small pilot study at Mass General Brigham. United Therapeutics, another developer of gene-edited pig organs, just won FDA approval for ...